New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis

Diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is presently based on mainly clinical symptoms. BPS/IC can be considered as a worst-case scenario of bladder overactivity of unknown origin, including bladder pain. Usually, patients are partially or completely resistant to anticholin...

Full description

Bibliographic Details
Main Authors:	Neuhaus, Jochen, Schwalenberg, Thilo, Horn, Lars-Christian, Alexander, Henry, Stolzenburg, Jens-Uwe
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199109/

id	pubmed-3199109
recordtype	oai_dc
spelling	pubmed-31991092011-10-25 New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis Neuhaus, Jochen Schwalenberg, Thilo Horn, Lars-Christian Alexander, Henry Stolzenburg, Jens-Uwe Research Article Diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is presently based on mainly clinical symptoms. BPS/IC can be considered as a worst-case scenario of bladder overactivity of unknown origin, including bladder pain. Usually, patients are partially or completely resistant to anticholinergic therapy, and therapeutical options are especially restricted in case of BPS/IC. Therefore, early detection of patients prone to develop BPS/IC symptoms is essential for successful therapy. We propose extended diagnostics including molecular markers. Differential diagnosis should be based on three diagnostical “columns”: (i) clinical diagnostics, (ii) histopathology, and (iii) molecular diagnostics. Analysis of molecular alterations of receptor expression in detrusor smooth muscle cells and urothelial integrity is necessary to develop patient-tailored therapeutical concepts. Although more research is needed to elucidate the pathomechanisms involved, extended BPS/IC diagnostics could already be integrated into routine patient care, allowing evidence-based pharmacotherapy of patients with idiopathic bladder overactivity and BPS/IC. Hindawi Publishing Corporation 2011 2011-10-19 /pmc/articles/PMC3199109/ /pubmed/22028706 http://dx.doi.org/10.1155/2011/639479 Text en Copyright © 2011 Jochen Neuhaus et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Neuhaus, Jochen Schwalenberg, Thilo Horn, Lars-Christian Alexander, Henry Stolzenburg, Jens-Uwe
spellingShingle	Neuhaus, Jochen Schwalenberg, Thilo Horn, Lars-Christian Alexander, Henry Stolzenburg, Jens-Uwe New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis
author_facet	Neuhaus, Jochen Schwalenberg, Thilo Horn, Lars-Christian Alexander, Henry Stolzenburg, Jens-Uwe
author_sort	Neuhaus, Jochen
title	New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis
title_short	New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis
title_full	New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis
title_fullStr	New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis
title_full_unstemmed	New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis
title_sort	new aspects in the differential diagnosis and therapy of bladder pain syndrome/interstitial cystitis
description	Diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is presently based on mainly clinical symptoms. BPS/IC can be considered as a worst-case scenario of bladder overactivity of unknown origin, including bladder pain. Usually, patients are partially or completely resistant to anticholinergic therapy, and therapeutical options are especially restricted in case of BPS/IC. Therefore, early detection of patients prone to develop BPS/IC symptoms is essential for successful therapy. We propose extended diagnostics including molecular markers. Differential diagnosis should be based on three diagnostical “columns”: (i) clinical diagnostics, (ii) histopathology, and (iii) molecular diagnostics. Analysis of molecular alterations of receptor expression in detrusor smooth muscle cells and urothelial integrity is necessary to develop patient-tailored therapeutical concepts. Although more research is needed to elucidate the pathomechanisms involved, extended BPS/IC diagnostics could already be integrated into routine patient care, allowing evidence-based pharmacotherapy of patients with idiopathic bladder overactivity and BPS/IC.
publisher	Hindawi Publishing Corporation
publishDate	2011
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199109/
_version_	1611482728065138688

New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis

Similar Items